Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07246681 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Lignin in Treatment of Helicobacter Pylori Infection

StatusCompleted
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date changed from estimate of Feb 15, 2026 to Aug 15, 2026 Show 4 more changesShow less
    • Study completion date changed from estimate of Mar 15, 2026 to Sep 15, 2026
    • Trial completed
    • Eligibility criteria expanded, about 9 words
    • Publications: details revised at 1 of 1 entry
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical trial is to learn if drug hydrolyzed lignin works to treat H pylori infection in adults. It will also learn about the safety of drug lignin n the sitting of H pylori infection, and if it halts the side effects associated with H pylori triple therapy. The main questions it aims to answer are: * Does drug hydrolyzed lignin improve the H pylori eradiation rate when it is added to the standard triple therapy used in treatment of H pylori? * What medical problems do participants experience when taking drug hydrolyzed lignin? Researchers will compare drug hydrolyzed lignin to a placebo (a look-alike substance that contains no drug) to see if drug hydrolyzed lignin works to treat H pylori. Participants will: * Take drug hydrolyzed lignin or a placebo every day for 2 weeks beside the standard triple therapy * Visit the clinic once every 1 week for checkup and questionnaire filling * Check for H pylori eradication after treatment
Trial Details
NCT Number NCT07246681
Lead Sponsor Zagazig University
Collaborators: EVERGREEN MEDICAL COMPANY, Kafrelsheikh University, Al-Azhar University, Ain Shams University, Egypt, Security Forces Hospital Riyadh, Saudi Arabia, Alyousif Hospital, Alkhobar, Saudi Arabia
Conditions
(from sponsor)		 HELICOBACTER PYLORI INFECTIONS
Enrollment 70 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov